Home › Liver Cancer (Hepatocellular Carcinoma) › NCT07291076
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria * Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC). * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Participants must have no prior systemic therapy for advanced/ unresectable HCC. * Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria * Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence. * Participants must not have an organ transplant or autoimmune disease. * Other protocol-defined Inclusion/Exclusion criteria apply.
About the study
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
What is being tested
- Pumitamig (drug)
- Ipilimumab (drug)
Sponsor: Bristol-Myers Squibb · Participants: 198 · Started: Mar 16, 2026
Contact the study team
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · Phone: 855-907-3286
Official record on ClinicalTrials.gov — NCT07291076
Locations in the U.S.
| California | City Of Hope, Duarte Local Institution - 0070, Los Angeles (Not yet recruiting) |
| Illinois | Local Institution - 0107, Chicago (Not yet recruiting) |
| Michigan | Local Institution - 0134, Detroit (Not yet recruiting) |
| New Jersey | John Theurer Cancer Center at Hackensack University Medical Center, Hackensack |
| New York | Laura and Isaac Perlmutter Cancer Center at NYU Langone, Mineola |
| Oregon | Providence Portland Medical Center, Portland Providence St. Vincent Medical Center, Portland |
| Tennessee | Tennessee Oncology, Nashville Vanderbilt University Medical Center, Nashville |
| Washington | Local Institution - 0083, Seattle (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.